

ANTARES PHARMA INC  
Form 8-K  
May 19, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 15, 2006**

---

**ANTARES PHARMA, INC.**

(Exact name of registrant specified in its charter)

---

**Delaware**  
(State or other jurisdiction

of incorporation)

**1-32302**  
(Commission File Number)

**41-1350192**  
(I.R.S. Employer

Identification No.)

**707 Eagleview Boulevard, Suite 414 Exton, PA**  
(Address of principal executive offices)

**19341**  
(Zip Code)

**Registrant's telephone, including area code: (610) 458-6200**

**Not applicable.**

(Former name and former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2. below):

## Edgar Filing: ANTARES PHARMA INC - Form 8-K

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition.**

On May 15, 2006, Antares Pharma, Inc. (the Company) issued a press release announcing the Company's financial results for its first fiscal quarter ended March 31, 2006.

A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press Release dated May 15, 2006.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTARES PHARMA, INC.

Date: May 19, 2006

By: /s/ ROBERT F. APPLE

Name: Robert F. Apple

Title: Senior Vice President and Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Document</b>
99.1	Press Release dated May 15, 2006.